Table 1.

Characteristics and demographics of the included studies

Study	Dx	Sample size	Female (%)	Age	Dosing	Psychiatric comorbidities	Study design	Dropout	Serious AE
Grob et al. [28]	Cancer	12	91.6	36–58	Oral single dose, 0.20 mg/kg	Yes. Specific psychiatric disorders were not mentioned	Double-blind RCT	0	No
Griffiths et al. [23]	Cancer	56	49.0	56.3 (10.0)	Oral single dose, 0.32 mg/kg (22 or 30 mg)	Adjustment disorder; dysthymia; GAD, and MDD	Double-blind RCT	5	No
Ross et al. [29]	Cancer	31	62.1	56.3 (12.9)	Oral single dose, 0.3 mg/kg	Adjustment disorder and GAD	Double-blind RCT	3	No
Agin-Liebes et al. [30]	Cancer	15	60.0	53 (13.5)	Oral single dose, 0.3 mg/kg	Adjustment disorder and GAD	Long-term follow-up after RCT	1	No
Anderson et al. [24]	HIV/cancer	18	0.0	59.2 (4.4)	Oral single dose, 0.30–0.36 mg/kg	Mood disorder, anxiety disorder, and insomnia	Open-label single-arm trial	0	No

AE, adverse event; Dx, diagnosis; GAD, generalized anxiety disorder; MDD, major depressive disorder; RCT, randomized controlled trial